| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 267 | 2021 |
| Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ... Blood advances 4 (7), 1311-1320, 2020 | 151 | 2020 |
| A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies CA Lachowiez, S Loghavi, Z Zeng, T Tanaka, YJ Kim, H Uryu, S Turkalj, ... Blood cancer discovery 4 (4), 276-293, 2023 | 74 | 2023 |
| Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, T Kadia, N Daver, ... American journal of hematology 97 (8), 1035-1043, 2022 | 60 | 2022 |
| Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia CA Lachowiez, N Long, J Saultz, A Gandhi, LF Newell, B Hayes-Lattin, ... Blood Advances 7 (9), 1899-1909, 2023 | 57 | 2023 |
| Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax+/-azacitidine in IDH1-mutated hematologic malignancies. CA Lachowiez, G Borthakur, S Loghavi, Z Zeng, TM Kadia, L Masarova, ... Journal of Clinical Oncology 38 (15_suppl), 7500-7500, 2020 | 55 | 2020 |
| Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax CA Lachowiez, S Loghavi, K Furudate, G Montalban-Bravo, A Maiti, ... Blood advances 5 (8), 2173-2183, 2021 | 54 | 2021 |
| Acute myeloid leukemia: from mutation profiling to treatment decisions C DiNardo, C Lachowiez Current hematologic malignancy reports 14, 386-394, 2019 | 53 | 2019 |
| Venetoclax in acute myeloid leukemia–current and future directions C Lachowiez, CD DiNardo, M Konopleva Leukemia & lymphoma 61 (6), 1313-1322, 2020 | 52 | 2020 |
| Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study CA Lachowiez, PK Reville, H Kantarjian, E Jabbour, G Borthakur, N Daver, ... The Lancet Haematology 9 (5), e350-e360, 2022 | 48 | 2022 |
| Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome CD DiNardo, S Venugopal, C Lachowiez, K Takahashi, S Loghavi, ... Blood advances 7 (11), 2378-2387, 2023 | 41 | 2023 |
| Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients M Khanlari, CC Yin, K Takahashi, C Lachowiez, G Tang, S Loghavi, I Bah, ... Leukemia 36 (5), 1343-1350, 2022 | 35 | 2022 |
| A phase Ib/II study of ivosidenib with venetoclax+/-azacitidine in IDH1-mutated myeloid malignancies. CA Lachowiez, G Borthakur, S Loghavi, Z Zeng, TM Kadia, L Masarova, ... Journal of Clinical Oncology 39 (15_suppl), 7012-7012, 2021 | 29 | 2021 |
| Interim analysis of the phase 1b/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients … C Lachowiez, M Konopleva, TM Kadia, N Daver, S Loghavi, SA Wang, ... Blood 136, 18-20, 2020 | 26 | 2020 |
| Contemporary outcomes in IDH‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatment CA Lachowiez, PK Reville, H Kantarjian, E Jabbour, G Borthakur, N Daver, ... American journal of hematology 97 (11), 1443-1452, 2022 | 24 | 2022 |
| A phase Ib/II study of ivosidenib with venetoclax+/-azacitidine in IDH1-mutated hematologic malignancies. CA Lachowiez, JS Garcia, G Borthakur, S Loghavi, Z Zeng, GD Tippett, ... Journal of Clinical Oncology 40 (16_suppl), 7018-7018, 2022 | 21 | 2022 |
| Building on foundations: Venetoclax-based combinations in the treatment of acute myeloid leukemia E Oyogoa, E Traer, J Tyner, C Lachowiez Cancers 15 (14), 3589, 2023 | 15 | 2023 |
| Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia CA Lachowiez, H Atluri, CD DiNardo Therapeutic advances in hematology 13, 20406207221093964, 2022 | 13 | 2022 |
| Clinical correlates of venetoclax-based combination sensitivities to augment acute myeloid leukemia therapy CA Eide, SE Kurtz, A Kaempf, N Long, SK Joshi, T Nechiporuk, A Huang, ... Blood cancer discovery 4 (6), 452-467, 2023 | 12 | 2023 |
| Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents D Hammond, S Loghavi, SA Wang, MY Konopleva, TM Kadia, NG Daver, ... Blood cancer journal 13 (1), 148, 2023 | 10 | 2023 |
